Pharma needs new blood to re-invent itself

The pharma industry should be re-inventing itself, "not re-trenching," the Association of the British Pharmaceutical Industry's director general, Dr. Richard Barker, said at the Economist conference this week. A key element of that re-invention? Bringing new talent into the insular pharma world from outside the industry. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.